openPR Logo
Press release

Acute Lymphocytic Leukemia Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, ROA, MOA and Companies involved by DelveInsight | Novartis, Jazz Pharmaceuticals, Takara Bio, Cellectis, AbbVie, vAutolus, Celgene

09-10-2024 06:52 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Acute Lymphocytic Leukemia Clinical Trials

Acute Lymphocytic Leukemia Clinical Trials

(Albany, USA) DelveInsight's, "Acute Lymphocytic Leukemia Pipeline Insight" report provides comprehensive insights about 150+ companies and 160+ pipeline drugs in the Acute Lymphocytic Leukemia pipeline landscape. It covers the Acute Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report
• DelveInsight's Acute Lymphocytic Leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
• The leading Acute Lymphocytic Leukemia companies working in the market include PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, vAutolus Limited, Juventas Cell Therapy Ltd., Pinze Life technology Co. Ltd., Celgene, and others.
• Promising Acute Lymphocytic Leukemia Pipeline Therapies in the various stages of development include Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), and others.
• December 2023: Curon Biopharmaceutical (Shanghai) Co. Ltd. announced a study of Phase 1 & 2 clinical trials for CN201. This study is designed in 2 parts as described below: Phase Ib (dose escalation and expansion) and Phase II. If in Phase Ib it is observed in adult subjects at doses with manageable risk and antitumor activity, studies in pediatric subjects can be initiated to explore safety and efficacy in pediatric subjects, as well as pharmacokinetic profiles.
• December 2023: Takara Bio Inc. announced a study of Phase 1 & 2 clinical trials for TBI-1501. CD19-CAR-T will be administered in the split dose. Phase 2 recommended dose will be applied for phase 1 portion. The investigator assesses efficacy of CD19-CAR-T in accordance with study-specific criteria, at 8 week after the infusion of CD19-CAR-T (or at the time of termination). The investigator also assesses the safety during the follow-up period. Long-term follow-up study is conducted at frequency of once a year for 15 years after the infusion of CD19-CAR-T in reference to guidelines of FDA.
• December 2023: Amgenannounced a study of Phase 3 clinical trials for Blinatumomab and SOC chemotherapy regimen. The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemotherapy.
• December 2023: H. Lee Moffitt Cancer Center and Research Instituteannounced a study of Phase 2 clinical trials for Tecartus. This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy.

Request a sample and discover the recent advances in Acute Lymphocytic Leukemia Treatment Drugs @ Acute Lymphocytic Leukemia Pipeline Outlook Report- https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

In the Acute Lymphocytic Leukemia pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Acute Lymphocytic Leukemia clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Acute Lymphocytic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Acute Lymphocytic Leukemia Overview
Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. "Acute" means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. ""Lymphocytic"" means it develops from early (immature) forms of lymphocytes, a type of white blood cell.

Find out more about Acute Lymphocytic Leukemia Therapeutics Assessment @ Acute Lymphocytic Leukemia Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Acute Lymphocytic Leukemia Emerging Drugs Profile
• CPX-351: Jazz Pharmaceuticals
• JZP-458: Jazz Pharmaceuticals
• UCART22: Cellectis
• JZP-341: Jazz Pharmaceuticals

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment
There are approx. 150+ key Acute Lymphocytic Leukemia companies which are developing the Acute Lymphocytic Leukemia pipeline therapies. The Acute Lymphocytic Leukemia companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others.

DelveInsight's Acute Lymphocytic Leukemia Pipeline Report covers around 160+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous.
• Molecule Type

Acute Lymphocytic Leukemia Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Learn more about the emerging Acute Lymphocytic Leukemia Pipeline Therapies @ Acute Lymphocytic Leukemia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Acute Lymphocytic Leukemia Pipeline Report
• Coverage- Global
• Acute Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Acute Lymphocytic Leukemia Companies- PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, vAutolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.
• Acute Lymphocytic Leukemia Pipeline Therapies- Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), and others.

Dive deep into rich insights for new drugs for Acute Lymphocytic Leukemia Treatment, Visit @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Acute Lymphocytic Leukemia Executive Summary
3. Acute Lymphocytic Leukemia Overview
4. Acute Lymphocytic Leukemia Pipeline Therapeutics
5. Acute Lymphocytic Leukemia Therapeutic Assessment
6. Acute Lymphocytic Leukemia- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Acute Lymphocytic Leukemia Collaboration Deals
9. Late Stage Products (Phase III and Phase II/III)
10. JZP-458: Jazz Pharmaceuticals
11. Mid Stage Products (Phase II)
12. CPX-351: Jazz Pharmaceuticals
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. UCART22: Cellectis
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. JZP-341: Jazz Pharmaceuticals
19. Inactive Products
20. Acute Lymphocytic Leukemia Companies
21. Acute Lymphocytic Leukemia Products
22. Acute Lymphocytic Leukemia Unmet Needs
23. Acute Lymphocytic Leukemia Market Drivers and Barriers
24. Acute Lymphocytic Leukemia Future Perspectives and Conclusion
25. Acute Lymphocytic Leukemia Analyst Views
26. Acute Lymphocytic Leukemia Companies
27. Appendix

For further information on the Acute Lymphocytic Leukemia Pipeline therapeutics, reach out to Acute Lymphocytic Leukemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Epithelioid Sarcoma Market: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market
• Ventricular Fibrillation Market: https://www.delveinsight.com/report-store/atrial-fibrillation-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Lymphocytopenia Market: https://www.delveinsight.com/report-store/lymphocytopenia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-epidemiology-forecast
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Primary Progressive Multiple Sclerosis Ppms Market: https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-pipeline-insight
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Surgical Stapling Devices Market: https://www.delveinsight.com/report-store/surgical-stapling-devices-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
• Goitre Market: https://www.delveinsight.com/report-store/goitre-market
• Pharma Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Primoridal Dwarfism Market: https://www.delveinsight.com/report-store/primordial-dwarfism-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-pipeline-insight
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Hereditary Spastic Paraplegias Market: https://www.delveinsight.com/report-store/hereditary-spastic-paraplegias-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/ventricular-dysfunction-market
• Alagille Syndrome Market: https://www.delveinsight.com/report-store/alagille-syndrome-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Cerebral Vein Thrombosis Market: https://www.delveinsight.com/report-store/cerebral-vein-thrombosis-market
• Contraceptive Devices Market: https://www.delveinsight.com/report-store/contraceptive-devices-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Ankylosing Spondylitis Bekhterevs Disease Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Atrophic Vaginitis Market: https://www.delveinsight.com/report-store/atrophic-vaginitis-market
• Diffuse Cutaneous Systemic Sclerosis Market: https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market
• Idiopathic Membranous Nephropathy Market: https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Chronic Idiopathic Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Crohns Disease Cd Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Helicobacter Pylori Infections Market: https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
• Juvenile Rheumatoid Arthritis Market: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-market
• Acromegaly Market: https://www.delveinsight.com/report-store/acromegaly-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Chronic Plaque Psoriasis Market: https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
• Post-transplant Lymphoproliferative Disease Market: https://www.delveinsight.com/report-store/post-transplant-lymphoproliferative-disorder-market
• Wet-age Related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Gastric Neuroendocrine Tumors Market: https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Lymphocytic Leukemia Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, ROA, MOA and Companies involved by DelveInsight | Novartis, Jazz Pharmaceuticals, Takara Bio, Cellectis, AbbVie, vAutolus, Celgene here

News-ID: 3650251 • Views:

More Releases from DelveInsight Business Research

Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Companies
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics. DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,

All 5 Releases


More Releases for Acute

Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth